Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 4/20 | 0.49 |
| ▸ | TTK | P33981 | 2/20 | 0.45 |
| ▸ | EIF2AK3 | Q9NZJ5 | 2/20 | 0.45 |
| ▸ | IGF1R | P08069 | 3/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 3/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | CLK2 | P49760 | 2/20 | 0.39 |
| ▸ | CLK3 | P49761 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | TAF1 | P21675 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30183541 | 1.00 | ATR (0.49) | ATRTTKEIF2AK3IGF1RDYRK1A | |
| SCHEMBL30183118 | 0.94 | ATR (0.43) | ATRTTKEIF2AK3CDK2KDR | |
| SCHEMBL20649055 | 0.94 | ATR (0.43) | ATRTTKEIF2AK3CDK2KDR | |
| SCHEMBL20649357 | 0.93 | ATR (0.40) | ATRTTKEIF2AK3CDK2KDR | |
| SCHEMBL30183165 | 0.93 | ATR (0.40) | ATRTTKEIF2AK3CDK2KDR | |
| SCHEMBL20649010 | 0.93 | ATR (0.40) | ATRTTKEIF2AK3AURKAAURKB | |
| SCHEMBL30183571 | 0.93 | ATR (0.40) | ATRTTKEIF2AK3AURKAAURKB | |
| SCHEMBL20649043 | 0.92 | KIT (0.41) | ATRTTKEIF2AK3CDK2KDR | |
| SCHEMBL30183431 | 0.92 | KIT (0.41) | ATRTTKEIF2AK3CDK2KDR | |
| SCHEMBL20649178 | 0.92 | ATR (0.52) | ATRTTKEIF2AK3DYRK1AAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110997678-B | Pyrazoloquinazoline derivatives as choline kinase inhibitors | 内尔维亚诺医疗科学公司 | 2023-02-21 | — | — | CN | claimed |
| US-11117901-B2 | Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2021-09-14 | — | — | US | claimed |
| US-20200131188-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-04-30 | — | — | US | claimed |
| CN-110997678-A | Pyrazoloquinazoline derivatives as choline kinase inhibitors | 内尔维亚诺医疗科学公司 | 2020-04-10 | — | — | CN | claimed |
| CN-110997678-B | Pyrazoloquinazoline derivatives as choline kinase inhibitors | 内尔维亚诺医疗科学公司 | 2023-02-21 | — | — | CN | disclosed |
| US-11117901-B2 | Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2021-09-14 | — | — | US | disclosed |
| US-11117901-B2 | Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2021-09-14 | — | — | US | disclosed |
| US-20200131188-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-04-30 | — | — | US | disclosed |
| US-20200131188-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-04-30 | — | — | US | disclosed |
| CN-110997678-A | Pyrazoloquinazoline derivatives as choline kinase inhibitors | 内尔维亚诺医疗科学公司 | 2020-04-10 | — | — | CN | disclosed |
| WO-2019011715-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131188-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS | CHKA, CHKB, NADK | ATR 599/4885TTK 115/4885EIF2AK3 2115/4885 |
| US-11117901-B2 | Substituted pyrazolo[4,3-h]quinazolines as choline kinase inhibitors | CHKA, CHKB, NADK | ATR 621/4885TTK 196/4885EIF2AK3 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.